Skip to main content
    N

    Niagen Bioscience, Inc. (NAGE)

    Official site

    CONSUMER DEFENSIVE • BIOTECHNOLOGY • NASDAQ

    $2.04
    +0.03 (+1.49%)

    Market Cap: $159.19M

    Last updated: Nov 17, 2026 at 4:16 PM ET

    Niagen Bioscience, Inc. (NAGE) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Niagen Bioscience (NAGE) has a market cap of $159.19M and an enterprise value of $89.68M. It holds $69.51M more cash than debt, 43.67% of its market cap.

    Total Valuation

    Enterprise value is 43.67% below the market cap, as cash exceeds debt.

    Market Cap$159.19M
    Enterprise Value$89.68M
    Latest price (Nov 17, 2026)$2.04

    Key Dates

    The next earnings report is expected on Mar 2, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 2, 2027 (expected)
    Last Earnings DateNov 4, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count fell 0.22% in the quarter ended Sep 30, 2026 and grew 2.07% a year over 2 years.

    Shares Outstanding79.15M
    Shares Change (YoY)-0.79%
    Shares Change (QoQ)-0.22%
    Share Count Growth (2Y CAGR)+2.07%

    Valuation Ratios

    Sales and book value multiples are 1.3x and 1.9x.

    P/E Ratio42.9x
    P/S Ratio1.3x
    Forward P/S1.3x
    P/B Ratio1.9x
    P/TBV Ratio2.1x
    P/OCF Ratio32.6x

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 8.7x EBITDA.

    EV / Earnings8.8x
    EV / Sales0.7x
    EV / EBITDA8.7x

    Price Statistics

    The stock is down 70.31% over 52 weeks and trades 22.14% below its 50-day average.

    Beta (1Y)1.69
    52-Week Change-70.31%
    1-Month Change-18.40%
    3-Month Change-35.65%
    6-Month Change-44.41%
    5-Year Change-62.36%
    10-Year Change-15.58%
    Total Return (1Y)-70.31%
    Total Return (3Y CAGR)+12.57%
    Total Return (5Y CAGR)-17.97%
    Return vs SPY (1Y)-81.82%
    Max Drawdown (1Y)-71.45%
    Max Drawdown (3Y)-86.05%
    Sharpe Ratio (1Y)-2.34
    Correlation with SPY (1Y)0.45
    50-Day Average$2.62
    200-Day Average$3.68
    52-Week Range$1.97 to $7.12
    RSI (14 Days)35.6
    Average Volume (20 Days)579.03K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 5.93x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio5.93x
    Quick Ratio4.71x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is 12.33% over the last 12 months, against a 5-year average of -23.86%.

    Return on Equity (ROE)12.33%
    Return on Assets (ROA)9.42%
    ROE (5Y Average)-23.86%
    ROA (5Y Average)-11.53%
    ROIC (5Y Average)20.06%
    Asset Turnover1.18x
    Inventory Turnover2.15x
    Receivables Turnover15.86x
    Cash Conversion Cycle107 days

    Taxes

    Income tax took 7.37% of pretax income over the last 12 months.

    Income Tax (TTM)$815.00K
    Effective Tax Rate7.37%

    Scores

    NAGE has an Altman Z-Score of 4.08, in the safe zone above 2.99, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.

    Altman Z-Score4.08
    Altman Z ZoneSafe
    Piotroski F-Score5 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $122.29M over the last 12 months is down 1.94% from the 12 months before.

    Revenue$122.29M
    Revenue Growth (YoY)-1.94%
    Gross Profit$78.10M
    Operating Income$4.78M
    Pretax Income$11.05M
    Net Income$10.24M
    Reported EPS (TTM)$0.05

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 76.43% of the $108.69M in total assets.

    Cash and Equivalents$69.51M
    Total Debt$0
    Net Cash$69.51M
    Net Cash Per Share$0.88
    Working Capital$83.31M
    Shareholder Equity$83.07M
    Book Value Per Share$1.05
    Tangible Book Value$77.94M
    Tangible Book Per Share$0.98
    Total Assets$108.69M
    Total Liabilities$25.62M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow$4.88M
    FCF Per Share$0.06
    Depreciation and Amortization$1.07M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 3.90%, against a 5-year average of -10.47%.

    Gross Margin63.86%
    Operating Margin3.90%
    Pretax Margin9.04%
    Net Margin8.37%
    Gross Margin (5Y Average)61.56%
    Operating Margin (5Y Average)-10.47%
    Net Margin (5Y Average)-9.41%

    Growth

    Revenue grew 21.56% a year over 3 years.

    Revenue Growth (3Y CAGR)+21.56%
    Revenue Growth (5Y CAGR)+16.91%
    Book Value Per Share Growth (2Y CAGR)+54.67%
    Tangible Book Per Share Growth (2Y CAGR)+50.19%

    Revenue and profit by year

    Dividends and Yields

    NAGE does not pay a dividend.

    Earnings Yield2.33%
    Buyback Yield3.17%
    Shareholder Yield3.17%

    Stock Splits

    The last split was a 1-for-3 reverse split on Apr 13, 2016.

    Last Split DateApr 13, 2016
    Split TypeReverse split
    Split Ratio1:3

    Peer Position

    Against 7 similar companies, NAGE has the highest P/E.

    P/E Ratio42.9x vs 11.1x median
    P/S Ratio1.3x vs 0.4x median
    Revenue Growth (Trailing 4 Quarters, YoY)-1.94% vs +1.21% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 2.92% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+2.92%
    EPS Growth Forecast (1Y CAGR)-88.07%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About NAGE

    What is NAGE's market cap?

    Niagen Bioscience has a market cap of $159.19M. Its enterprise value, which adds debt and subtracts cash, is $89.68M.

    What is NAGE's P/E ratio?

    Niagen Bioscience has a trailing P/E ratio of 42.9x.

    How many shares of NAGE are outstanding?

    Niagen Bioscience has 79.15M shares outstanding. The count is down 0.79% from a year earlier.

    Does NAGE pay a dividend?

    No. Niagen Bioscience does not pay a dividend.

    How much debt does NAGE have?

    Niagen Bioscience has $0 of total debt and $69.51M of cash and equivalents, a net cash position of $69.51M.